Prognostic value of Ki67: comparison of the proliferation index between meningiomas with and without infiltration of glial tissue
Keywords:
meningioma; immunohistochemistry; Ki67; prognosisAbstract
Background: Although generally considered benign, meningiomas can cause significant morbidity and mortality. Histologic grade is the most useful morphologic predictor of recurrence.
Objectives: To compare Ki67 labeling index between meningioma grade I and meningioma grade II with brain invasion.
Methods: We analyzed 20 primary meningioma, 10 of which were grade I and 10 of which were grade II. Ki67 proliferative indices were determined in all cases.
Results: The patient population consisted of 9 males and 11 females with mean age of 60 years. For meningioma grade I, the Ki67 labeling index varied between 1 and 15% with an average of 3.1%. A diagnosis of gradeII meningiomas was made solely on the basis of brain invasion. The immunohistochemical study noted that the Ki67 index varied between 1 and 20% with an average of 6,8%.
Conclusion: The Ki67 labeling index shows a significant increase from grade I to grade II. It may provide useful prognostic information.
Downloads
References
Martin N, Mokhtari K. Les tumeurs intracrâniennes. Sauramps médicale ; 2009. pages 377-411.
Mawrin C, Perry A, Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010; 99(3):379-91.
Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006; 5: 1045-54.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellision DW, Figarella-Branger D, Reifenberger G, von Deimling A. Health Organisation classification of tumours of the Central Nervous System. Lyon: IARC Press; 2016. p.163.
Vranic A, Popovic M, Co¨ r A, Prestor B, Pizem J. Mitotic Count, Brain Invasion, and Location Are Independent Predictors of Recurrence-Free Survival in Primary Atypical and MalignantMeningiomas: A Study of 86 Patients. Neurosurgery 2010; 67:1124-1132.
Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004; 363: 1535-43.
Alahmadi H, Croul SE. Pathologie and genetics of meningiomas. Semin Diagn Pathol 2011; 28: 314-24.
Barresi V1, Caffo M2, Tuccari G. Classification of human meningiomas: lights, shadows, and future perspectives. J Neurosci Res. 2016; 94: 1604-12.
Guadagno E, Del Basso De Caro M, Pignatiello S, Sciammarella C, Solari D, Cappabianca P and al. Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role. J Neurooncol. 2016; 129: 405-13.
Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. ki-67 proliferative index predicts Clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 2007; 27: 114-20.
Gauchotte G1, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C and al. Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. Am J Surg Pathol. 2012; 36: 283-91.
Ozen O, Demirhan B, Altinörs N. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol. 2005; 24: 219-24.
Perry A, Louis DN, Scheithauer BW, Budka H, Von Deimling A. Meningiomas. In: David N. Louis Ohgaki H, Wiestler DO, K. Cavenee W. Health Organisation classification of tumours of the Central Nervous System. Lyon: IARC Press; 2007. p.163.
Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA and al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004; 27: 238-45.
Liu Y, Shi J, Chen M, Cao YF, Liu YW, Pan J and al. Periostin: a novel prognostic predictor for meningiomas. J Neurooncol. 2015; 121: 505-12.
